This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


AbbVie Inc.

Drug Names(s): J867

Description: Asoprisnil is a novel selective steroid receptor modulator. Its major metabolite is J912, and other structurally related compounds represent a new class of progesterone receptor (PR) ligands that exhibit partial agonist and antagonist activities in vivo. Asoprisnil demonstrates a high degree of receptor and tissue selectivity, with high-binding affinity for PR, moderate affinity for glucocorticoid receptor (GR), low affinity for androgen receptor (AR), and no binding affinity for estrogen or mineralocorticoid receptors.

Deal Structure: Asoprisnil was originally developed by EnTec (a subsidiary of Jenapharm; Schering) and later developed by TAP Pharmaceutical Products.

In 2006, Bayer acquired Schering AG.

In March 2008, Takeda Pharmaceutical and Abbott concluded their TAP Pharmaceutical Products joint venture.

Partners: Bayer AG

Asoprisnil News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug